

Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS Address:

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.

09/121,781

07/23/98

LAROSA

l";

LKS98-04

HELEN E. WENDLER, ESQ. HAMILTON BROOK SMITH & REYNOLDS, P.C. TWO MILITIA DRIVE LEXINGTON MA 02421-4799

EXAMINER SALIMI, A **ART UNIT** PAPER NUMBER 1648

DATE MAILED:

09/19/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Approant(s)

Larosa G. J.

Examiner

Office Action Summary

ALI R. SALIMI

Group Art Unit 1648



X Responsive to communication(s) filed on 7/26/00	<u> </u>
☐ This action is FINAL.	
☐ Since this application is in condition for allowance except for for in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C	
A shortened statutory period for response to this action is set to e is longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extensions 37 CFR 1.136(a).	respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s) 9-44	is/are withdrawn from consideration.
Claim(s)	
☐ Claim(s) 1-8 and 45-52	
Claim(s)	
☐ Claims	
Application Papers See the attached Notice of Draftsperson's Patent Drawing F The drawing(s) filed on is/are objected	
☐ The proposed drawing correction, filed on	is _approved _disapproved.
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority un All Some* None of the CERTIFIED copies of the received.	
☐ received in Application No. (Series Code/Serial Number	er)
received in this national stage application from the In-	ternational Bureau (PCT Rule 17.2(a)).
*Certified copies not received: Acknowledgement is made of a claim for domestic priority	
Acknowledgement is made of a claim for domestic priority	under 35 U.S.C. 9 119(e).
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152	s). <u>4,7</u>
SEE OFFICE ACTION ON THE	E FOULOWING PAGES

Application/Control Number: 09/121,781 Page 2

Art Unit: 1648

DETAILED ACTION

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1648.

Election/Restriction

Applicant's election with traverse of Group I claims 1-8, 45-52 in Paper No. 12 is acknowledged. The traversal is on the ground(s) that the subject matter of Groups I, II, and III overlap and the search for the said groups would not provide serious burden. In addition, applicants agree that the said inventions are patentably distinct. This is not found persuasive because examination of all groups would be unduly burdensome, the literature search, particularly relevant in this art, is not co-extensive and is much more important in evaluating the burden search. Clearly different searches and issues are involved in the examination of each group. For these reasons the restriction requirement is deemed to be proper.

The requirement is still deemed proper and is therefore made FINAL.

Claims 9-44 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected groups, the requirement having been traversed in Paper No. 12.

Applicants are reminded to cancel the claims to the non elected claims.

Application/Control Number: 09/121,781 Page 3

Art Unit: 1648

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who

has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention

thereof by the applicant for patent.

Claims 1-8, 45-52 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Lind

et al (US Patent No. 6,084,075).

The above cited patent meets the broad limitations of the claims (see the claims). The

claims are directed to a product. The product disclosed in the above cited patent appears to be

identical or so similar that is indistinguishable from the product claimed by the applicants.

Applicants are reminded that the Patent Office does not have facilities to perform physical

comparisons between the claimed product and similar prior art products. Hence, the disclosure of

the above cited patent anticipates the claimed invention. Applicants are reminded that the intended

use of a product does not carry patentable weight.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

Application/Control Number: 09/121,781

Art Unit: 1648

•

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-8, 45-52 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Frade et al (J. Clin. Invest. 1997).

The above cited article disclosed an antibody raised against CCR2 (see page 498, left column, last paragraph, and right column, last full paragraph). Applicants are reminded that antibodies exhibit wide range of binding capability. The product disclosed in the above cited patent appears to be identical or so similar that is indistinguishable from the product claimed by the applicants. Applicants are reminded that the Patent Office does not have facilities to perform physical comparisons between the claimed product and similar prior art products. Hence, the disclosure of the above cited patent anticipates the claimed invention.

Claims 1-8, 45-52 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Frade et al (J. Immunology, 1997).

The above cited article disclosed an antibody raised against CCR2 (see page 5577, left column, last paragraph). Applicants are reminded that antibodies exhibit wide range of binding capability. The product disclosed in the above cited patent appears to be identical or so similar that is indistinguishable from the product claimed by the applicants. Applicants are reminded that the Patent Office does not have facilities to perform physical comparisons between the claimed product and similar prior art products. Hence, the disclosure of the above cited patent anticipates the claimed invention.

Page 4

Application/Control Number: 09/121,781

Art Unit: 1648

Claims 1-8, 45-52 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Lind

Page 5

et al (WO 97/31949, 9/4/1997).

The above cited patent meets the broad limitations of the claims (see the claims). The claims are

directed to a product. The product disclosed in the above cited patent appears to be identical or

so similar that is indistinguishable from the product claimed by the applicants. Applicants are

reminded that the Patent Office does not have facilities to perform physical comparisons between

the claimed product and similar prior art products. Hence, the disclosure of the above cited

patent anticipates the claimed invention. Applicants are reminded that the intended use of a

product does not carry patentable weight.

No claims are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Ali R. Salimi whose telephone number is (703) 305-7136. The examiner

can normally be reached on Monday-Friday from 9:00 Am to 6:00 Pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

James Housel, can be reached on (703) 308-4027. The fax phone number for this Group is (703)

305-7401.

Application/Control Number: 09/121,781

Page 6

Art Unit: 1648

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Ali R. Salimi

9/18/2000

ALI P. SALINI SIMARY EXAMINER